New York · Nonprofit
THE OVARIAN CANCER RESEARCH FUND INC
THE OVARIAN CANCER RESEARCH FUND INC (New York) receives grants from 257 organizations whose IRS filings report $11,823,613 to it, the largest being FIDELITY INVESTMENTS CHARITABLE GIFT FUND ($1,143,443). 116 of them have funded it in more than one year, and 54% of the money arrives through donor-advised or pass-through sponsors rather than from an institution directly.
- Revenue FY2024
- $10M
- Funders on record
- 257
- Grants received
- $12M
- Net assets
- $23M
What The Ovarian Cancer Research Fund Inc does
Mission
Ovarian cancer research alliance (ocra) is committed to preventing, developing better treatments for and ultimately curing ovarian and related gynecologic cancers through innovative research, raising awareness and ensuring the best care possible through advocacy and support for patients and families.
As stated on its FY2024 Form 990.
Programs
Ovarian cancer research alliance was founded in 1994 (as the ovarian cancer research fund, inc.) and is a full-spectrum organization funding medical research, advocating on behalf of patients and providing support and resources to patients and their families.ovarian cancer is the deadliest of all gynecologic cancers and ranks fifth as the cause of cancer death in women. In 2024, there were 19,680 new cases of ovarian cancer and 12,740 deaths from the disease in the united states. The accomplishments of ocra's programs reflect our commitment to the ovarian and gynecologic cancer communities. Since 1998, ocra has awarded 435 grants for ovarian and related cancer research to physicians and scientists at 99 leading medical centers, which is an investment totaling over $129 million. Thanks to the generosity of our donors, our investigators are working on many fronts to defeat ovarian cancer. By developing innovative strategies for early detection and exploring the genetics that increase risk for ovarian cancer, we hope to save women's lives by finding the cancer early or stopping it before it even starts. Researchers are gaining insights into the many types of ovarian and related…
$7,227,647 spentof which $6,318,064 as grants73% of program spendingBeyond our conference, ocra has additional patient education and support programs and engages in advocacy on behalf of women with gynecologic cancers. Our website is a comprehensive source of educational information, and throughout the course of the year we hold a series of free, educational webinars on a range of topics related to the latest research, treatment, and survivorship.ocra offers free genetic testing to qualified high risk individuals and facilitates access to certified genetic counselors. Since the launch of the program, ocra has helped over 3,000 people learn about their genetic risk for gynecologic cancer. Ocra's patient-support line is staffed by our social work team during business hours monday through friday and is available to anyone seeking information, support, patient navigation, or resource referrals (medical advice is not provided). Our woman to woman program is a peer-to-peer support program for women with gynecologic cancer. Ocra offers both a national woman to woman program and provides financial support to help hospitals and other organizations start local woman to woman programs, which are now at more than 19 sites across the country. Our staying…
$1,708,288 spentof which $35,000 as grants17% of program spendingEach year, ocra brings together ovarian cancer patients, survivors and caregivers at the international gynecologic cancer conference, a three day-long event filled with informational sessions featuring expert speakers, fun and community. In 2024, more than 600 people from all 50 states and 14 countries came together virtually for this event. The spirit of unity and hope is always strong and attendees can learn more about their diagnosis, treatment, and survivorship. Sessions feature top ovarian and gynecologic cancer experts who generously give of their time, presenting the latest in treatments, research, managing recurrence, genetics, nutrition, caretaker and supporter care, support for young women, advocacy, and so much more.
$982,758 spentof which $75,000 as grants$301,023 earned by the program10% of program spending
The 3 programs described on its FY2024 Form 990, listed largest first by expense. Program spending in total: $9,918,693.
The organization over time
Each line starts at 100 in 2017, so what you read is the shape rather than the size: 150 means half as much again as 2017, 50 means half. The number beside each label in the key is where it ended. The shaded band is where the middle 50% of its peers' revenue would sit, given their growth.
Balance sheet
Total assets and total liabilities at each year end, in dollars. The largest one-year move in total assets was 2021 to 2022, from $33M to $38M (+14%).
How it's funded, over time
Each bar is one year's revenue split into where it came from, and every bar is the same height — these are shares, not amounts, so a year that raised twice as much looks the same size. Hover a bar for the split.
Government-grant reliance: 2020 5% · 2021 3%. Grants only. Government contracts and fees sit inside program revenue.
85% of THE OVARIAN CANCER RESEARCH FUND INC’s revenue is contributions — more donation-reliant than the typical peer (80% for the typical peer).
Surplus & reserves
Operating surplus or deficit each year, and months of liquidity in hand. 5 of the last 8 reported years ran a deficit.
reserve
Leadership and staff
The officers, directors, trustees and key employees listed on each return. Joined and no longer listed compare each filing with the year before, matching people by surname and first initial; a year after a gap, or a roster under three people, has no comparison.
Chief executive
Audra L Moran
President & CEO
Board chair
John Orrico
Chair
As listed on its FY2024 Form 990.
Who funds it, year by year
2017 → 2023: the base broadened from 47 funders to 87 funders, grant income rose $747k → $1.7M.
42 of 257 of your funders are donor-advised or pass-through sponsors (tagged DAF) — 54% of grant dollars received. That money is really individual donors directing a sponsor; the institutions to cultivate are the non-DAF funders.
From the IRS filings of THE OVARIAN CANCER RESEARCH FUND INC’s funders (the co-funder graph). Top 30 of 257 funders by total. Association, not causation. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How concentrated its funding is
THE OVARIAN CANCER RESEARCH FUND INC has a broad base — no single funder exceeds 10% of grant income, and it takes 9 funders to reach half.
the vertical line marks half of all grant income — 9 funders to its left
67% of the income these shares are computed over arrives through pass-through sponsors or from payers whose filings do not say what kind of payment it is. Concentration is still measured over all of it, because the money is real; what it does not support is a claim about how many institutions have chosen to fund THE OVARIAN CANCER RESEARCH FUND INC.
Largest funder’s share by year: 2017 21% · 2018 18% · 2019 13% · 2020 14% · 2021 44% · 2022 19% · 2023 29% — growing more concentrated.
“Effective funders” = inverse Herfindahl index (1 / Σ shareᵢ²) — the number of equal-sized funders that would give the same concentration. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How long its funders stay
37% of THE OVARIAN CANCER RESEARCH FUND INC's funders are still giving 3 years after their first grant; 45% give in more than one year at all.
Share of funders still giving k years after their first recorded grant, pooled across every acquisition cohort. A funder counts as retained in a year only if it made a grant that year. Measured to FY2023, the last fiscal year that has finished arriving — a funder cannot be counted as lapsed in a year most filers have not reached.
Where its funders are
54% of THE OVARIAN CANCER RESEARCH FUND INC's grant income arrives through donor-advised or pass-through sponsors, whose addresses record where the money is held rather than where the donor is. Of the $5.4M that is directly attributable, 76% of it comes from funders outside New York, across 35 states.
In-state vs out-of-state, by year
Funder states come from each funder’s own filing. $6.4M arriving through sponsors registered in 21 states is excluded from the map and the split above: a sponsor holds money on a donor’s behalf, so its registered address would place those dollars somewhere no donor need ever have been. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
Against its field
THE OVARIAN CANCER RESEARCH FUND INC receives grants from 257 organizations whose IRS filings report $12M to it.
this organization peer median middle 50% of peers· 828 philanthropy nonprofits $10M–$100M, FY2024
Organizations like THE OVARIAN CANCER RESEARCH FUND INC
Organizations whose mission and program text most resemble this one, by semantic similarity over every organization in the US filings — the closest peers, and often the clearest route to shared or prospective funders.
In New York
Nationally
Read directly from this organization’s own Form 990, as neutral context.
Where the money goes
73% of spending goes to programs.
Governance
Public support
76%
Share of support from the public (Schedule A) — the basis for its public-charity status.
Footprint & structure
Files a return copy in 27 states
Part of a family of 1 related entity
- Ovarian Cancer National Alliance · exempt
Screen this organization
A dated, signed PDF of the compliance screen for THE OVARIAN CANCER RESEARCH FUND INC: IRS status (Business Master File, Publication 78, auto-revocation), the OFAC sanctions lists, the Internal Revenue Bulletin, and California registration, with the Rev. Proc. 2018-32 §8.01 reliance elements stated element by element. Generated from the current files at the moment you download it.
Screens are triage, not determinations; a source that cannot be read reports not screened, never clear. Screen this nonprofit · How the screen works · on the API as GET /api/screening/{ein}?format=pdf
Questions and answers
- Who funds THE OVARIAN CANCER RESEARCH FUND INC?
- THE OVARIAN CANCER RESEARCH FUND INC (New York) receives grants from 257 organizations whose IRS filings report $11,823,613 to it, the largest being FIDELITY INVESTMENTS CHARITABLE GIFT FUND ($1,143,443). 116 of them have funded it in more than one year, and 54% of the money arrives through donor-advised or pass-through sponsors rather than from an institution directly.
- How many funders does THE OVARIAN CANCER RESEARCH FUND INC have?
- IRS filings report 257 organizations giving $11,823,613 in grants to THE OVARIAN CANCER RESEARCH FUND INC, 116 of which have funded it in more than one year.
- Who is the largest funder of THE OVARIAN CANCER RESEARCH FUND INC?
- FIDELITY INVESTMENTS CHARITABLE GIFT FUND is the largest funder on record, with $1,143,443 in grants. The full list of funders is on this page.
- How can an organization like THE OVARIAN CANCER RESEARCH FUND INC find more funders?
- Start with the funders already giving here, then look at the foundations that back similar organizations in New York. The funding by cause and by state pages list the largest funders for a given area and how to approach them.
These figures are read directly from IRS Form 990 / 990-PF e-file XML: this organization’s own return for FY2024 (financials across 2017–2024), and the filings of 257 funders that report grants to it. “On record” means captured in the filings we have parsed — a funder that does not e-file, or whose grant detail is not itemized, will not appear. Filings run roughly 12–24 months behind. Trends on this page end at FY2023, the last fiscal year that has finished arriving; later years are shown and marked, and move no figure. Data on this page was exported October 14, 2026. What this page cannot tell you · view filing